Last reviewed · How we verify
Nebulized 3% sodium chloride solution — Competitive Intelligence Brief
marketed
Mucolytic/secretion mobilizer
Pulmonology/Respiratory
Small molecule
Live · refreshed every 30 min
Target snapshot
Nebulized 3% sodium chloride solution (Nebulized 3% sodium chloride solution) — NYU Langone Health. Nebulized hypertonic saline draws fluid into the airways through osmotic gradient, hydrating secretions and promoting mucus clearance.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Nebulized 3% sodium chloride solution TARGET | Nebulized 3% sodium chloride solution | NYU Langone Health | marketed | Mucolytic/secretion mobilizer |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Mucolytic/secretion mobilizer class)
- NYU Langone Health · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Nebulized 3% sodium chloride solution CI watch — RSS
- Nebulized 3% sodium chloride solution CI watch — Atom
- Nebulized 3% sodium chloride solution CI watch — JSON
- Nebulized 3% sodium chloride solution alone — RSS
- Whole Mucolytic/secretion mobilizer class — RSS
Cite this brief
Drug Landscape (2026). Nebulized 3% sodium chloride solution — Competitive Intelligence Brief. https://druglandscape.com/ci/nebulized-3-sodium-chloride-solution. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab